Tag: Biotechnology | Page 9 | NAI 500 | Page 9

- English
  - 简体中文
  - 繁體中文

Home
Biotechnology

Filter

America’s R&D exodus is a hidden market risk

Feb 18, 2026

Moderna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge

Why Alnylam Soared 6%: One Analyst Says the Biotech’s Growth Story Is Just Getting Started

Feb 17, 2026

BFF Bank (BFF IM) Crashes to Record Low on Probe

Feb 17, 2026

CRISPR Therapeutics Soars as Partner Vertex Drops Optimistic 2026 Sales Guidance

CRISPR Therapeutics Soars as Partner Vertex Drops Optimistic 2026 Sales Guidance

Feb 13, 2026

Aluminum Slumps as Trump Mulls Narrower Tariffs; AA Hit

Feb 13, 2026

Shorted-to-the-hilt KalVista rockets 39% as Chiesi swoops in with $1.9bn cash bid

From AbbVie to CRISPR: 6 Must-Watch Healthcare Stocks for 2026

Feb 12, 2026

Is Pfizer’s Turnaround Story Worth a Closer Look?

Is Pfizer’s Turnaround Story Worth a Closer Look?

Feb 11, 2026

AI Comms Spike: SINCH TWLO BAND RNG ERIC on Watch

Feb 10, 2026

Apple’s Tim Cook Steps Down: What the CEO Transition Means for Investors

Novo Nordisk Crashes 68%: Is It Time to Buy the Dip?

Feb 8, 2026

AV Tech Moves: 688007.SH, 005930.KS, HPQ, LOGI, BAR.BR

Feb 6, 2026

5 Institutional-Approved High-Dividend Pharmaceutical Stocks for Passive Income Investors

Why Did This Pharma Stock Defy the Market Downturn Today?

Feb 5, 2026

5 High-Dividend Value Stocks to Buy as Market Valuations Stretch to Extremes

6 Top Healthcare Stocks to Buy Now, According to Analysts

Feb 4, 2026

Can Lightspeed Secure an Earnings Turnaround via Strategic Overhaul

Can Pfizer Stage a Comeback in 2026?

Feb 2, 2026

Shorted-to-the-hilt KalVista rockets 39% as Chiesi swoops in with $1.9bn cash bid

Fees as Low as 0.08%! 7 Top Healthcare Funds and ETFs to Watch in 2026

Jan 28, 2026

Three Biotech Stocks Crushed the S&P 500 — Analysts Still Back Just One

From Weight Loss Drugs to Cancer Vaccines: A Contrarian Bet on Two Biotech Stocks

Jan 27, 2026

NVDA, TSLA, AAPL, INTC, RDWR drive tech tape

Jan 26, 2026

FDA Delays Lilly’s Weight-Loss Pill: Is the Stock Still a Buy for 2026?

FDA Delays Lilly’s Weight-Loss Pill: Is the Stock Still a Buy for 2026?

Jan 25, 2026

Buying Back, Paying Up: Suncor and Cogeco Defied the Sell-Off

Massive Upside Potential: Two Canadian Growth Stocks for Risk-Tolerant Investors

Jan 21, 2026

Life Science, Precious Metals